| Bioactivity | Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis[1]. |
| Target | Guanylate cyclase (GCC) |
| Invitro | Indusatumab vedotin (0.4-25 μg/mL；72 小时) 在胰腺癌细胞系中引起抗增殖作用[1]。Indusatumab vedotin (12.5 μg/mL；24 小时) 使 MIA PaCa-2 和 PANC-1 细胞的细胞周期停滞在 G2/M 期，并引起 P-Hitone H3 的产生[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Indusatumab vedotin 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | Indusatumab vedotin (10 mg/kg；静脉注射；每周一次，至少持续 17 天) 显着降低肿瘤的生长速度[1]。Indusatumab vedotin 在携带六种不同异种移植模型之一的小鼠中显示出与暴露密切相关的生物活性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1514889-12-3 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schreiber AR, et al. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018;5(1):42-49. [2]. Teng S W, et al. Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models[J]. Cancer Research, 2014, 74(19_Supplement): 4649-4649. |